Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration.
- 1 July 1994
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 90 (1) , 421-426
- https://doi.org/10.1161/01.cir.90.1.421
Abstract
BACKGROUND DSPA (Desmodus salivary plasminogen activator) is a new thrombolytic agent corresponding to a natural plasminogen activator discovered in the saliva of the vampire bat Desmodus rotundus. Compared with tissue plasminogen activator (TPA), DSPA, produced in a recombinant cell line, is more fibrin cofactor dependent than TPA. METHODS AND RESULTS The thrombolytic properties of DSPA and TPA were compared in a canine model of copper coil-induced coronary thrombosis. All dogs received heparin 200 IU/kg IV and SC. Whereas controls did not reperfuse within 180 minutes (none of six), intravenous bolus administration of DSPA at 25, 50, and 100 micrograms/kg resulted in a 100% incidence (6 of 6) of recanalization within 37, 23, and 18 minutes, respectively. TPA at 63 and 125 micrograms/kg reopened the coronaries in 33% (two of six) and 50% (three of six) of cases within 40 minutes. Eighty-three percent (5 of 6) of the arteries were still patent 3 hours after 50 and 100 micrograms/kg DSPA, whereas only 20% (one of five) of all coronaries originally recanalized with both doses of TPA were still open at 3 hours. Plasma levels of alpha 2-antiplasmin decreased significantly only with 125 micrograms/kg TPA. The clearance of DSPA (2.3 to 3.5 mL.min-1.kg-1) was lower compared with TPA (11.4 to 20 mL.min-1.kg-1) due to a prolonged terminal half-life. CONCLUSIONS In a canine coronary thrombosis model, DSPA exhibited higher potency and recanalized coronary arteries faster and with a lower incidence of reocclusion than TPA. Its properties may translate into a higher efficacy in patients compared with available thrombolytic agents. The long half-life of DSPA may allow for single bolus administration in the treatment of acute myocardial infarction.Keywords
This publication has 15 references indexed in Scilit:
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- Towards improved thrombolytic therapyThe Lancet, 1993
- Dose-related efficacy and bleeding complications of double-chain tissue plasminogen activator in acute myocardial infarctionThe American Journal of Cardiology, 1993
- Plasmhogen Activators from the Saliva of Desmodus rotundus (Common Vampire Bat): Unique Fibrin SpecificityAnnals of the New York Academy of Sciences, 1992
- Double bolus administration of the novel recombinant plasminogen activator BM 06.022 improves coronary blood flow after reperfusion in a canine model of coronary thrombosisBlood Coagulation & Fibrinolysis, 1992
- The plasminogen activator family from the salivary gland of the vampire bat Desmodus rotundas: cloning and expressionGene, 1991
- Tissue Plasminogen Activator: The Biochemistry and Pharmacology of Variants Produced by MutagenesisAnnual Review of Pharmacology and Toxicology, 1990
- Paradoxical attenuation of fibrinolysis attributable to “plasminogen steal” and its implications for coronary thrombolysisCoronary Artery Disease, 1990
- Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinaseJournal of the American College of Cardiology, 1988
- Clot-Selective Coronary Thrombolysis with Tissue-Type Plasminogen ActivatorScience, 1983